The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
The European Society of Cardiology and the Harteraad see patient engagement as a partnership between patients, scientists and healthcare professionals that actively support their mission of reducing the burden of cardiovascular disease. Their aim is to listen and learn from patients how to:
Both organisations will be involved in two symposia to be organized in 2022 and 2023 by the TRAIN-HEART network to increase awarenss among early stage researchers on the importance of involving patients in desiging, conducting and dissemination their research.
Mon, 18 January
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
